| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Prepaid expenses and other current assets | 105 | |||
| Cash | 2,803 | |||
| Related party receivable | 143 | |||
| Total current assets | 3,051 | |||
| Total assets | 3,051 | |||
| Other accrued liabilities | 44 | |||
| Accounts payable | 219 | |||
| Total current liabilities | 263 | |||
| Total liabilities | 263 | |||
| Accumulated deficit | -397,788 | |||
| Preferred stock, at amounts paid in, 0.001 par value per share 5,000,000 shares authorized, 890,345 and 950,000 shares issued and outstanding at june 30, 2025 and december31, 2024, respectively | 1 | |||
| Common stock, at amounts paid in, 0.001 par value per share 225,000,000 shares authorized, 1,330,234 and 914,234 shares issued and outstanding at june 30, 2025 and december31, 2024, respectively | 1 | |||
| Additional paid-in capital | 400,574 | |||
| Total stockholders equity | 2,788 | |||
| Total liabilities and stockholders equity | 3,051 | |||
TITAN PHARMACEUTICALS INC (TTNP)
TITAN PHARMACEUTICALS INC (TTNP)